Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

flects its current core products and does not reflect any future revenue or earnings from any product currently before the FDA awaiting approval or clearance.

In fiscal 2010, the Company will adopt Accounting Standards Codification (ASC) 470-20 (formerly FASB Staff Position No. APB 14-1), "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)," which will increase the Company's interest expense by approximately $17 million in the first quarter and $71 million for the full year of fiscal 2010. Such amount is reflected in the EPS guidance below. However, as the additional interest expense is a non-cash item, the Company will include this as a reconciling item to arrive at non-GAAP adjusted net income and EPS.

First Quarter Fiscal 2010 (Quarter ending December 26, 2009):

    -- The Company expects first quarter fiscal 2010 revenues to be
       approximately $400 million to $405 million, comparable with the
       fourth quarter of fiscal 2009, reflecting an increase in revenues
       in the GYN Surgical and Diagnostics segments, offset by an
       anticipated decrease in the Breast Health segment, primarily related
       to the Selenia full field digital system.
    -- The Company expects EPS to be approximately $0.06 to $0.08 and
       non-GAAP adjusted EPS to be approximately $0.24 to $0.26.

Fiscal 2010 (Year ending September 25, 2010):

    -- The Company expects fiscal 2010 revenues to be approximately $1.625
       billion to $1.650 billion, driven primarily by an increase in
       revenues in the GYN Surgical and Diagnostics segments, as well as
       from Service, with continued softness in the Breast Health segment,
       primarily related to the mammography product line.

       In addition, the Company has discontinued three products that
       contributed the following revenues in Fiscal 2009:
       -- The AEG 
'/>"/>
SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... a motive of enabling women the best possible avenues to ... free breast cancer screening// in Dubai, scheduled to begin next ... in the emirate, UAE nationals, expatriates and visitors, to avail ... is absolutely essential to achieve better treatment outcomes. ...
... leaders in Wales are calling on the National Assembly for ... and release// patients from a heavy financial burden. ... people to park at hospitals is an indirect tax on ... hospital clinics do so by car. Often, these people have ...
... Anti-retrovirals have always been a blessing for the HIV patients, ... double blessing; ARV’s are capable of halting// the progress of ... is well known that HIV-infection could lead to mental illness. ... to HIV. Dr Michelle Rogers, a psychiatrist, says: "There were ...
... from Bristol University has developed a technique, using luciferase, to ... in detecting// damage to heart cells after a heart attack. ... for rapid recovery from cardiac arrests and heart surgery. This ... of Biological Chemistry. ,Dr Elinor Griffiths and her ...
... published the findings of the head to head trial of ... The study was an effort in drawing a methodical comparison ... ED and diabetes, hypertension, and/or hyperlipidemia. The results showed that ... use of this drug. ,A total of 1,057 ...
... records in paper form and scattered across the offices ... need those records// most--when you're lying on a gurney ... to do. Sometimes they do the wrong thing: in ... from medical mistakes, and 1.5 million people suffer from ...
Cached Medicine News:Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 2Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 4Health News:A glowing energy measure for heart cells 2Health News:Patients suffering ED happy with Vardenafil drugs 2Health News:Dying for Data 2
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
ELISA for detection of Anti-Gliadin IgG....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgG antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
Medicine Products: